Galinpepimut-S (GPS)
Acute Myeloid Leukemia (AML)
Key Facts
About SELLAS Life Sciences
SELLAS Life Sciences is a clinical-stage biotech focused on developing transformative cancer therapies, with a mission centered on high-unmet-need oncology indications. Its strategy leverages two core platforms: a WT1-targeting peptide vaccine (GPS) and a highly selective CDK9 inhibitor (SLS009), both supported by strong clinical data and strategic partnerships. The company is approaching a pivotal inflection point with the final analysis of its Phase 3 REGAL trial in AML expected in 2026, backed by a strengthened balance sheet from recent warrant exercises.
View full company profileAbout SELLAS Life Sciences
SELLAS Life Sciences is a clinical-stage biotech focused on developing transformative cancer therapies, with a mission centered on high-unmet-need oncology indications. Its strategy leverages two core platforms: a WT1-targeting peptide vaccine (GPS) and a highly selective CDK9 inhibitor (SLS009), both supported by strong clinical data and strategic partnerships. The company is approaching a pivotal inflection point with the final analysis of its Phase 3 REGAL trial in AML expected in 2026, backed by a strengthened balance sheet from recent warrant exercises.
View full company profileAbout SELLAS Life Sciences
SELLAS Life Sciences is a clinical-stage biotech focused on developing transformative cancer therapies, with a mission centered on high-unmet-need oncology indications. Its strategy leverages two core platforms: a WT1-targeting peptide vaccine (GPS) and a highly selective CDK9 inhibitor (SLS009), both supported by strong clinical data and strategic partnerships. The company is approaching a pivotal inflection point with the final analysis of its Phase 3 REGAL trial in AML expected in 2026, backed by a strengthened balance sheet from recent warrant exercises.
View full company profileTherapeutic Areas
Other Acute Myeloid Leukemia (AML) Drugs
| Drug | Company | Phase |
|---|---|---|
| Mipletamig (APVO436) | Aptevo Therapeutics | Phase 1/2 |
| lomonitinib | Lomond Therapeutics | IND-Enabling |
| lonitoclax | Lomond Therapeutics | Phase 1 |
| Menin Inhibitor | Lomond Therapeutics | Discovery |
| AB8939 | AB Science | Phase 1 |
| Small-Molecule Therapeutic | AIkido Labs | Pre-clinical |
| ADI-PEG 20 (pegargiminase) | Polaris Pharma | Phase 1 |
| NC525 | NextCure | Preclinical |
| ACD-101 | Advanced Cellular Dynamics | Phase 1 |
| ABD-3001 | Advanced Biodesign | Phase 1 |
| HC-7366 | HiberCell | Phase 1b |
| Prexigebersen (BP1001) | Bio-Path Holdings | Phase 2 |